Table 2.
General characteristics of reviewed mycobacterial studies involving MSIs (n = 121).
| Attribute | Human (%)a | Animal (%)a |
|---|---|---|
| Mycobacterial group responsible for MSIs | ||
| M. tuberculosis Complex (MTBC) | 87 (71.9%) | 8 (6.6%) |
| Non-tuberculous Mycobacteria (NTM)b | 18 (14.9%) | 9 (7.4%) |
| Geographic locationc | ||
| Africab | 28 (23.1%) | 4 (3.3%) |
| Asiab | 31 (25.6%) | 0 (0.0%) |
| Europeb | 20 (16.5%) | 8 (6.6%) |
| North America | 15 (12.4%) | 3 (2.5%) |
| Oceania | 1 (0.8%) | 0 (0.0%) |
| South Americab | 11 (9.1%) | 3 (2.5%) |
| Publication year (decade) | ||
| Pre-2000 | 12 (9.9%) | 0 (0.0%) |
| 2000-2009b | 32 (26.4%) | 4 (3.3%) |
| 2010-2019 | 54 (44.6%) | 13 (10.7%) |
| 2020 | 7 (5.8%) | 1 (0.8%) |
| MSI detection methodd | ||
| Insertion Sequence Based RFLPb | 34 (28.1%) | 3 (2.5%) |
| Variable Number Tandem Repeat | 44 (36.4%) | 12 (9.9%) |
| Whole Genome Sequencing | 12 (9.9%) | 3 (2.5%) |
| Spoligotyping | 14 (11.6%) | 6 (5.0%) |
| Region Specific PCRb | 16 (13.2%) | 0 (0.0%) |
| Othere | 11 (9.1%) | 0 (0.0%) |
Studies were grouped based on multiple criteria (host, geographical location, publication date and methods used). Totals for some sections may not add up to 100% as certain studies met multiple criteria and were therefore counted more than once.
The subsection contains studies counted under more than one criterion.
Excluding one study (Gan et al., 2016), which used information on isolates from a global database.
Not counting methods that were unable to identify MSIs in the respective studies. Methods are briefly described in Table 3 and details are included in Supplementary Table 2.
Includes methods such as phage typing, PFGE, etc. Details are provided in Supplementary Table 2.